Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 6/20 | 0.49 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PNMT | P11086 | 1/20 | 0.40 |
| ▸ | ACP3 | P15309 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29463258 | 0.79 | TAAR1 (0.71) | TAAR1MAOBIDO1HTR2AHTR2C | |
| SCHEMBL39655 | 0.79 | TAAR1 (0.71) | TAAR1MAOBIDO1HTR2AHTR2C | |
| Iodide SCHEMBL11221836 | 0.78 | TAAR1 (0.69) | TAAR1MAOBIDO1HTR2AHTR2C | |
| Bromide SCHEMBL31513704 | 0.78 | TAAR1 (0.69) | TAAR1MAOBIDO1HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL26616857 | 0.78 | TAAR1 (0.69) | TAAR1MAOBIDO1HTR2AHTR2C | |
| Bromide SCHEMBL11233006 | 0.78 | TAAR1 (0.69) | TAAR1MAOBIDO1HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL11220775 | 0.78 | TAAR1 (0.69) | TAAR1MAOBIDO1HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL30481169 | 0.75 | EPHX1 (0.44) | TAAR1MAOBIDO1ACP3 | |
| Ethylamine SCHEMBL4238530 | 0.74 | TAAR1 (0.65) | TAAR1MAOBIDO1HTR2AHTR2C | |
| SCHEMBL108337 | 0.73 | TAAR1 (0.67) | TAAR1MAOBIDO1LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117561061-A | Combination of 3- (imidazol-4-yl) -4- (amino) -benzenesulfonamide TEAD inhibitors with EGFR inhibitors and/or MEK inhibitors for the treatment of lung cancer | 医肯纳肿瘤学公司 | 2024-02-13 | — | — | CN | disclosed |